Format

Send to

Choose Destination
Leukemia. 2014 Mar;28(3):675-9. doi: 10.1038/leu.2013.225. Epub 2013 Jul 29.

Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients.

Author information

1
Unité de Génomique du Myélome, University Hospital, CRCT, INSERM U 1037, Université Paul Sabatier, Toulouse, France.
2
Service des Maladies du Sang, Hopital Claude Huriez, CHRU, Lille, France.
3
Service d'Epidémiologie, CHU Toulouse, Toulouse, France.
4
Hématologie Clinique, Hôpital Purpan, Toulouse, France.
5
Department of Hematology, University Hospital, Dijon, France.
6
Department of Hematology, University Hospital, Bordeaux, France.
7
Department of Hematology, University Hospital, Lyon, France.
8
Department of Hematology, University Hospital, Nancy, France.
9
CIC Inserm 0802, Centre Hospitalier Universitaire, Poitiers, France.
10
Department of Hematology, University Hospital, Paris, France.
11
Department of Hematology, University Hospital, Rennes, France.
12
Department of Hematology, University Hospital, Bobigny, France.
13
Department of Hematology, University Hospital, Grenoble, France.
14
Department of Hematology, University Hospital, St-Etienne, France.
15
Department of Hematology, University Hospital, Angers, France.
16
Department of Hematology, Institut Paoli Calmette, Marseille, France.
17
Department of Hematology, Centre Léon Bérard, Lyon, France.
18
Department of Hematology, University Hospital, Strasbourg, France.
19
Department of Hematology, University Hospital, Besancon, France.
20
Department of Hematology, Centre Francois Baclesse, Caen, France.
21
Department of Hematology, University Hospital, Caen, France.
22
Department of Hematology, Departmental Hospital, Annecy, France.
23
Department of Hematology, Departmental Hospital, Avignon, France.
24
Department of Hematology, Departmental Hospital, Toulon, France.
25
Department of Hematology, University Hospital, Nantes, France.

Abstract

Deletions of the 1p region appear as a pejorative prognostic factor in multiple myeloma patients (especially 1p22 and 1p32 deletions) but there is a lack of data on the real impact of 1p abnormalities on an important and homogeneous group of patients. To address this issue we studied by fluorescence in situ hybridization (FISH) the incidence and prognostic impact of 1p22 and 1p32 deletions in 1195 patients from the IFM (Institut Francophone du Myélome) cell collection. Chromosome 1p deletions were present in 23.3% of the patients (271): 15.1% (176) for 1p22 and 7.3% (85) for 1p32 regions. In univariate analyses, 1p22 and 1p32 appeared as negative prognostic factors for progression-free survival (PFS): 1p22: 19.8 months vs 33.6 months (P<0.001) and 1p32: 14.4 months vs 33.6 months (P<0.001); and overall survival (OS): 1p22: 44.2 months vs 96.8 months (P=0.002) and 1p32: 26.7 months vs 96.8 months (P<0.001). In multivariate analyses, 1p22 and 1p32 deletions still appear as independent negative prognostic factors for PFS and OS. In conclusion, our data show that 1p22 and 1p32 deletions are major negative prognostic factors for PFS and OS for patients with MM. We thus suggest that 1p32 deletion should be tested for all patients at diagnosis.

PMID:
23892719
PMCID:
PMC6140327
DOI:
10.1038/leu.2013.225
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center